Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.
Circulating tumor cells
Esophageal cancer
Non-metastatic
Prognostic
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Jul 2022
08 Jul 2022
Historique:
received:
04
04
2022
accepted:
30
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy. We prospectively collected CTC data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in our QUINTETT esophageal cancer randomized trial (NCT00907543). Patients were randomized to receive either neoadjuvant cisplatin and 5-fluorouracil (5-FU) plus radiotherapy followed by surgical resection (Neoadjuvant) or adjuvant cisplatin, 5-FU, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection (Adjuvant). CTCs were identified with the CellSearch® system before the initiation of any treatment (surgery or chemoradiotherapy) as well as at 6-, 12-, and 24-months post-treatment. The threshold for CTC positivity was one and the findings were correlated with patient prognosis. CTC data were available for 74 of 96 patients and identified in 27 patients (36.5%) at a median follow-up of 13.1months (interquartile range:6.8-24.1 months). Detection of CTCs at any follow-up visit was significantly predictive of worse disease-free survival (DFS;hazard ratio [HR]: 2.44; 95% confidence interval [CI]: 1.41-4.24; p=0.002), regional control (HR: 6.18; 95% CI: 1.18-32.35; p=0.031), distant control (HR: 2.93; 95% CI: 1.52-5.65;p=0.001) and overall survival (OS;HR: 2.02; 95% CI: 1.16-3.51; p=0.013). After adjusting for receiving neoadjuvant vs. adjuvant chemoradiotherapy, the presence of CTCs at any follow-up visit remained significantly predictive of worse OS ([HR]:2.02;95% [Cl]:1.16-3.51; p=0.013) and DFS (HR: 2.49;95% Cl: 1.43-4.33; p=0.001). Similarly, any observed increase in CTCs was significantly predictive of worse OS (HR: 3.14; 95% CI: 1.56-6.34; p=0.001) and DFS (HR: 3.34; 95% CI: 1.67-6.69; p<0.001). The presence of CTCs in patients during follow-up after tri-modality therapy was associated with significantly poorer DFS and OS regardless of timing of chemoradiotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Our aim was to establish if presence of circulating tumor cells (CTCs) predicted worse outcome in patients with non-metastatic esophageal cancer undergoing tri-modality therapy.
METHODS
METHODS
We prospectively collected CTC data from patients with operable non-metastatic esophageal cancer from April 2009 to November 2016 enrolled in our QUINTETT esophageal cancer randomized trial (NCT00907543). Patients were randomized to receive either neoadjuvant cisplatin and 5-fluorouracil (5-FU) plus radiotherapy followed by surgical resection (Neoadjuvant) or adjuvant cisplatin, 5-FU, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection (Adjuvant). CTCs were identified with the CellSearch® system before the initiation of any treatment (surgery or chemoradiotherapy) as well as at 6-, 12-, and 24-months post-treatment. The threshold for CTC positivity was one and the findings were correlated with patient prognosis.
RESULTS
RESULTS
CTC data were available for 74 of 96 patients and identified in 27 patients (36.5%) at a median follow-up of 13.1months (interquartile range:6.8-24.1 months). Detection of CTCs at any follow-up visit was significantly predictive of worse disease-free survival (DFS;hazard ratio [HR]: 2.44; 95% confidence interval [CI]: 1.41-4.24; p=0.002), regional control (HR: 6.18; 95% CI: 1.18-32.35; p=0.031), distant control (HR: 2.93; 95% CI: 1.52-5.65;p=0.001) and overall survival (OS;HR: 2.02; 95% CI: 1.16-3.51; p=0.013). After adjusting for receiving neoadjuvant vs. adjuvant chemoradiotherapy, the presence of CTCs at any follow-up visit remained significantly predictive of worse OS ([HR]:2.02;95% [Cl]:1.16-3.51; p=0.013) and DFS (HR: 2.49;95% Cl: 1.43-4.33; p=0.001). Similarly, any observed increase in CTCs was significantly predictive of worse OS (HR: 3.14; 95% CI: 1.56-6.34; p=0.001) and DFS (HR: 3.34; 95% CI: 1.67-6.69; p<0.001).
CONCLUSION
CONCLUSIONS
The presence of CTCs in patients during follow-up after tri-modality therapy was associated with significantly poorer DFS and OS regardless of timing of chemoradiotherapy.
Identifiants
pubmed: 35804307
doi: 10.1186/s12885-022-09846-0
pii: 10.1186/s12885-022-09846-0
pmc: PMC9264673
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
746Informations de copyright
© 2022. The Author(s).
Références
Br J Surg. 2007 Aug;94(8):984-91
pubmed: 17410638
N Engl J Med. 2021 Apr 1;384(13):1269-1271
pubmed: 33789017
Clin Cancer Res. 2007 Feb 1;13(3):920-8
pubmed: 17289886
Cancer Lett. 2010 Feb 1;288(1):99-106
pubmed: 19619935
Ann Surg. 2015 Jun;261(6):1124-30
pubmed: 25607767
Breast Cancer Res Treat. 1999 Aug;56(3):219-31
pubmed: 10573113
J Clin Oncol. 2000 Apr;18(7):1432-9
pubmed: 10735890
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
J Clin Pathol. 1960 Sep;13:414-24
pubmed: 13682365
Clin Transl Oncol. 2008 Jul;10(7):399-406
pubmed: 18628068
J Cancer Res Clin Oncol. 2003 Mar;129(3):192-8
pubmed: 12684893
Anticancer Res. 2000 Nov-Dec;20(6C):4739-44
pubmed: 11205210
Thorac Cancer. 2022 Jul;13(13):1898-1915
pubmed: 35611396
Cytometry A. 2007 Mar;71(3):154-62
pubmed: 17200956
J Mol Diagn. 2005 Nov;7(5):631-7
pubmed: 16258162
Ann Oncol. 2008 May;19(5):935-8
pubmed: 18212090
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Mol Pathol. 1997 Aug;50(4):209-11
pubmed: 9350305
Clin Colorectal Cancer. 2006 Jul;6(2):125-32
pubmed: 16945168
Clin Cancer Res. 2002 Sep;8(9):2879-82
pubmed: 12231531
Clin Cancer Res. 2007 May 15;13(10):2992-7
pubmed: 17505001
Dis Esophagus. 2008;21(8):690-6
pubmed: 18459988
Ann Oncol. 2010 Apr;21(4):729-733
pubmed: 19850639
Clin Colorectal Cancer. 2014 Jun;13(2):94-9
pubmed: 24332356
Pharmacogenomics. 2010 Mar;11(3):341-7
pubmed: 20235790
Lancet Oncol. 2009 Mar;10(3):233-9
pubmed: 19213602
Sci Rep. 2018 Mar 14;8(1):4522
pubmed: 29540708
Lancet Oncol. 2012 Jul;13(7):688-95
pubmed: 22677156
Ann Surg Oncol. 2008 Nov;15(11):3092-100
pubmed: 18766405
Ann Oncol. 2011 Jan;22(1):86-92
pubmed: 20603432
J Exp Clin Cancer Res. 2004 Sep;23(3):455-64
pubmed: 15595636
J Korean Med Sci. 1999 Dec;14(6):623-8
pubmed: 10642939
Curr Oncol. 2009 Aug;16(4):48-54
pubmed: 19672424
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Thorac Cancer. 2018 Aug;9(8):956-966
pubmed: 29893036
J Cancer Res Clin Oncol. 2011 Aug;137(8):1151-73
pubmed: 21681690
Surgery. 2003 Feb;133(2):162-9
pubmed: 12605177
Biotechnol Adv. 2013 Nov 15;31(7):1063-84
pubmed: 23999357
Br J Surg. 2004 Aug;91(8):1055-60
pubmed: 15286970
Ann Oncol. 2010 May;21(5):1006-12
pubmed: 19861577
J Clin Oncol. 2008 Oct 1;26(28):4551-6
pubmed: 18574157
Clin Cancer Res. 2008 Nov 1;14(21):7004-10
pubmed: 18980996
Breast Cancer Res. 2009;11(4):R46
pubmed: 19589136
J Clin Oncol. 2008 Jul 1;26(19):3213-21
pubmed: 18591556
J Clin Oncol. 2011 Apr 20;29(12):1556-63
pubmed: 21422424
Virchows Arch. 2001 Aug;439(2):109-17
pubmed: 11561750
J Clin Oncol. 2011 Apr 20;29(12):1547-55
pubmed: 21422427
Onco Targets Ther. 2018 Nov 12;11:8053-8061
pubmed: 30519047
BMC Cancer. 2020 Jun 22;20(1):581
pubmed: 32571299
Clin Exp Metastasis. 2009;26(7):751-8
pubmed: 19521785